Rhodiola Rosea in Adults With Attention Deficit/Hyperactivity Disorder

Hospital de Clinicas de Porto Alegre60 enrolled

Overview

This study evaluates the use of Rhodiola rosea in the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) in adults. Half of participants will receive Rhodiola rosea, while the other half will receive placebo.

Rhodiola rosea is an herbal medicine used for centuries in various medical conditions. Many randomized controlled trials have evaluated its usefulness in stress and fatigue. There were benefits in attention in some of these studies. Mild side effects and beneficial antioxidant properties make reasonable an assessment of its potential benefits in adults with ADHD. To our knowledge, Rhodiola rosea was never studied in ADHD.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

Attention Deficit/Hyperactivity Disorder

Interventions

RhodiolaDRUG

Rhodiola rosea 200mg pill up to four times a day

PlaceboDRUG

up to four times a day

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Fulfillment of Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, (DSM-5) diagnostic criteria for ADHD in Adults * Intelligence Quotient (IQ) above 70 * Eligibility to Rhodiola rosea Exclusion Criteria: * clinical contraindication fro Rhodiola rosea - * any unstable chronic illness without proper treatment (hypertension, heart, kidney or liver disease) * any significant neurological disease (delirium, dementia, epilepsy, AIDS, head trauma, multiple sclerosis, stroke, etc) * unstable psychiatric comorbidities requiring immediate treatment (risk of suicide, current Substance Use Disorder, etc.) * pregnant, nursing or absence of reliable contraception * current use of nicotine (\<30 days) * use of anticoagulants * current use of any psychoactive drug (\<30 days) * prior use of stimulants * current or lifetime psychosis- current or lifetime bipolar disorder

Locations (1)

Hospital de Clínicas de Porto Alegre

Porto Alegre, Rio Grande do Sul, Brazil

RECRUITING

Outcomes

Primary Outcomes

Change in Swanson, Nolan and Pelham Rating Scale - Version IV (SNAP-IV) adapted to adults

Time frame: Change from baseline SNAP-IV at 4 weeks

Secondary Outcomes

Change in Adult Self-Report Scale (ASRS)

Time frame: Change from baseline ASRS at 4 weeks

Central Contacts

Eugenio Grevet, PhD

CONTACT

55 51 3359-8094 ehgrevet@gmail.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.